The FDA has granted Fast Track designation for SAB Biotherapeutics' (NASDAQ:SABS) SAB-176, an investigational therapeutic for Type A and Type B influenza illness in high-risk patients, including those ...
Controversial Securities and Exchange Commission accounting guidance known as SAB 121 has been rescinded. SAB 121 has been viewed as a significant obstacle preventing banks from providing custody ...
SEC Staff Accounting Bulletin (SAB) 121 is no more. Today, SAB 122 rescinded the guidance of SAB 121 – the bulletin that “expressed the views of the staff regarding the accounting for obligations to ...
SAB-142 shows favorable safety and pharmacodynamic activity in Phase 1 trial, advancing to Phase 2b for type 1 diabetes. SAB BIO announced positive results from its Phase 1 trial of SAB-142, a novel ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback